Morgan Keegan Lowers Price Target On National Health Investors To $49

According to Morgan Keegan, National Health Investors NHI price target is lowered to $49. Morgan Keegan said that it bases its Outperform rating on National Health Investors on a view that the company has a strong portfolio and can use its underlevered balance sheet to make accretive new investments. “We are tweaking our earnings estimates, changing our 2011 FFO/FAD from $2.89/$2.83 to $2.85/$2.84 and our 2012 estimates from $3.05/$3.04 to $3.02/$3.00.” National Health Investors closed yesterday at $40.78.